{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:21:45Z","timestamp":1792012905695,"version":"4.4.0"},"reference-count":19,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T00:00:00Z","timestamp":1734825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis Care &amp;amp; Research"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This work aimed to evaluate the pharmacokinetics, efficacy, and safety of upadacitinib, an oral selective JAK inhibitor, in pediatric patients with polyarticular\u2010course juvenile idiopathic arthritis (pcJIA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In an open\u2010label, phase 1 study (SELECT\u2010YOUTH), enrolled patients, aged 2 to &lt;18 years with pcJIA, received body weight\u2013based upadacitinib doses using a twice\u2010daily oral solution or once\u2010daily extended\u2010release tablet based on their body weight and ability to swallow tablets. The study included a 7\u2010day pharmacokinetic assessment, followed by a long\u2010term efficacy and safety evaluation for up to 156 weeks, including an additional long\u2010term safety cohort. This interim analysis included available pharmacokinetic and safety data and efficacy data collected through week 48.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 57 patients received upadacitinib. The median time to maximum upadacitinib concentration was approximately three hours and one hour for the tablet and oral solution regimens, respectively; the harmonic mean functional half\u2010life was approximately five hours and two hours, respectively. Juvenile idiopathic arthritis American College of Rheumatology 30, 50, 70, 90, and 100 responses at week 12 were 91.8%, 89.8%, 69.4%, 49.0%, and 32.7%, respectively. Efficacy was generally maintained through week 48, and improvement in additional efficacy end points was also observed. At a median exposure duration of 412 days, 52 of 57 patients reported adverse events; of these, 6 experienced serious adverse events. Adverse events were predominately mild to moderate in severity and consistent with the known safety profile of upadacitinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This interim analysis demonstrates that the bodyweight\u2010based dosing regimen of upadacitinib was well tolerated and efficacious in pediatric patients with pcJIA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acr.25465","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T22:11:48Z","timestamp":1731622308000},"page":"584-593","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Pharmacokinetics, Efficacy, and Safety of Upadacitinib in Pediatric Patients With Polyarticular\u2010Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open\u2010Label, Phase 1 Trial"],"prefix":"10.1002","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-2987","authenticated-orcid":false,"given":"Hermine I.","family":"Brunner","sequence":"first","affiliation":[{"name":"University of Cincinnati, Cincinnati Children's Hospital Medical Center  Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1945-9255","authenticated-orcid":false,"given":"Anna","family":"Shmagel","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5491-7832","authenticated-orcid":false,"given":"Gerd","family":"Horneff","sequence":"additional","affiliation":[{"name":"Asklepios Clinic Sankt Augustin, Sankt Augustin, and University Hospital of Cologne  Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Foeldvari","sequence":"additional","affiliation":[{"name":"Hamburger Zentrum f\u00fcr Kinder und Jugendrheumatologie, am Klinikum Eilbek  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8792-4219","authenticated-orcid":false,"given":"Jordi","family":"Ant\u00f3n","sequence":"additional","affiliation":[{"name":"Hospital Sant Joan de D\u00e9u, Universitat de Barcelona  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8663-2401","authenticated-orcid":false,"given":"Athimalaipet V.","family":"Ramanan","sequence":"additional","affiliation":[{"name":"Bristol Royal Hospital for Children &amp; Translational Health Sciences, University of Bristol  Bristol United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8986-2189","authenticated-orcid":false,"given":"Yuli","family":"Qian","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Unnebrink","sequence":"additional","affiliation":[{"name":"AbbVie Deutschland GmbH &amp; Co. KG  Ludwigshafen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Hao","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi S.","family":"Camp","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser","family":"Khan","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4444-1230","authenticated-orcid":false,"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0959-2025","authenticated-orcid":false,"given":"Mohamed\u2010Eslam F.","family":"Mohamed","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,22]]},"reference":[{"issue":"2","key":"e_1_2_8_2_1","first-page":"390","volume":"31","author":"Petty RE","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.4274\/balkanmedj.2017.0111"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00332-8"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.209"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41390"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23853"},{"key":"e_1_2_8_8_1","volume-title":"Rinvoq (upadacitinib). Package insert","year":"2019"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01255-1"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.5091a"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00921-2"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400703"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00739-3"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0419-y"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.462"},{"key":"e_1_2_8_16_1","volume-title":"NDA 211675\/S\u2010021 and S\u2010022","year":"2024"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3441"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13146"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1543"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.576"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.25465","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:33:05Z","timestamp":1759419185000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.25465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,22]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1002\/acr.25465"],"URL":"https:\/\/doi.org\/10.1002\/acr.25465","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,22]]},"assertion":[{"value":"2024-05-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}